Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence

Author(s): Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, et al.

Abstract

Background and purpose:There is scant population-based information on functional outcome, survival, and recurrence for ischemic stroke subtypes.

Methods:We identified all residents of Rochester, Minnesota, with a first ischemic stroke from 1985 through 1989 using the resources of the Rochester Epidemiology Project medical records linkage system. After reviewing medical records and imaging studies, we assigned patients to 4 major ischemic stroke categories based on National Institute of Neurological Diseases and Stroke Data Bank criteria: large-vessel cervical or intracranial atherosclerosis with stenosis (ATH, n=74), cardioembolic (CE, n=132), lacunar (LAC, n=72), and infarct of uncertain cause (IUC, n=164). We used the Rankin disability score to assess functional outcome and the Kaplan-Meier product-limit method and Cox proportional hazards regression analysis with bootstrap validation to estimate rates and identify predictors of survival and recurrent stroke among these patients.

Results:Rankin disabilities were different across stroke subtypes at the time of stroke and 3 months and 1 year later (P=0.001). LAC was associated with milder deficits compared with other subtypes. Mean follow-up among the 442 patients in the cohort was 3.2 years. Estimated rates of recurrent stroke at 30 days were significantly different (P<0.001): ATH, 18.5% (95% CI 9.4% to 27.5%); CE, 5.3% (95% CI 1.2% to 9.6%); LAC, 1.4% (95% CI 0.0% to 4.1%); and IUC, 3. 3% (95% CI 0.4% to 6.2%). After adjusting for age, sex, and stroke severity, infarct subtype was an independent determinant of recurrent stroke within 30 days (P=0.0006; eg, risk ratio for ATH compared with CE=3.3, 95% CI 1.2 to 9.3) but not long term (P=0.07). Four of 25 recurrent strokes within 30 days were procedure-related, each in patients with ATH. Five-year death rates were significantly different (P<0.001): ATH, 32.2% (95% CI 21.1% to 43.2%); CE, 80.4% (95% CI 73.1% to 87.6%); LAC, 35.1% (95% CI 23.6% to 46.0%); and IUC, 48.6% (95% CI 40.5% to 56.7%). With adjustment for age, sex, cardiac comorbidity, and stroke severity, the subtype of ischemic stroke was an independent determinant of long-term (P=0.018; eg, risk ratio for ATH compared with cardioembolic=0.47, 95% CI 0.29 to 0.77) but not 30-day survival (P=0.2).

Conclusions:Early recurrence rates for ischemic stroke caused by ATH are higher than those for other subtypes and higher than previous non-population-based studies have reported. Some of the increased risk of early recurrence among patients with ATH may be iatrogenic. Patients with LAC have better poststroke functional status than those with other subtypes. Survival is poorest among those with ischemic stroke with a cardiac source of embolism.

Similar Articles

Ischemic stroke subtypes: a population-based study of incidence and risk factors

Author(s): Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, et al.

Thrombolysis with alteplase 3 to 4

Author(s): Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, et al.

The science of stroke: mechanisms in search of treatments

Author(s): Moskowitz MA, Lo EH, Iadecola C

von Willebrand factor: an emerging target in stroke therapy

Author(s): De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C

Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins

Author(s): André P, Denis CV, Ware J, Saffaripour S, Hynes RO, et al.

Shear-dependent changes in the three-dimensional structure of human von Willebrand factor

Author(s): Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, et al.

Deficiency of von Willebrand factor protects mice from ischemic stroke

Author(s): Kleinschnitz C, De Meyer SF, Schwarz T, Austinat M, Vanhoorelbeke K, et al.

Tissue plasminogen activator reduces neurological damage after cerebral embolism

Author(s): Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA

Tissue plasminogen activator

Author(s): Zivin JA, Lyden PD, DeGirolami U, Kochhar A, Mazzarella V, et al.

Quantal bioassay and stroke

Author(s): Zivin JA, Waud DR

Neuroprotective effects of anesthetic agents

Author(s): Kawaguchi M, Furuya H, Patel PM